Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Deferasirox

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    59 result(s) found for: Deferasirox. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2016-002282-61 Sponsor Protocol Number: CICL670FIC05 Start Date*: 2018-02-19
    Sponsor Name:Novartis Pharma AG
    Full Title: Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet (Jupiter)
    Medical condition: Transfusion-dependent Thalassemia, Non-transfusion-dependent Thalassemia
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002583-14 Sponsor Protocol Number: CICL670A2201 Start Date*: 2016-11-25
    Sponsor Name:Novartis Pharmaceuticals Corp
    Full Title: A Randomized, Open-label, Multi-center, Phase II Study to Evaluate the Safety and Efficacy of Deferasirox (ICL670) 20 mg/kg/Day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients...
    Medical condition: Sickle Cell Disease/ Iron Overload
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-001077-13 Sponsor Protocol Number: CICL670A2417 Start Date*: 2011-08-11
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: Estudio clínico multicéntrico, aleatorizado, comparativo, de distintos regímenes de administración de deferasirox en la tolerabilidad gastrointestinal (GI), en pacientes con síndrome mielodisplásic...
    Medical condition: Sobrecarga de hierro de riesgo bajo o intermedio (int-1) en pacientes con síndrome mielodisplásico (SMD) con ferritina > 1000 mcg/L en la selección o antecedentes de transfusión de por lo menos 20 ...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10022979 Iron excess HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023217-61 Sponsor Protocol Number: 10/0174 Start Date*: 2012-01-27
    Sponsor Name:University College London
    Full Title: A phase IV, open-label, partial cross-over partial parallel, randomized, multi-centre study to compare the gastrointestinal tolerability of once daily oral deferasirox, when administered before or ...
    Medical condition: transfusional haemosiderosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10019024 Haemosiderosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004995-17 Sponsor Protocol Number: NL7507301820 Start Date*: 2021-03-11
    Sponsor Name:AMsterdam UMC-AMC
    Full Title: Low dose iron chelation as TReatment of Oxidative stress in Sickle cell disease; TROS study
    Medical condition: Sickle cell disease (an hereditary hemoglobinopathy)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003775-30 Sponsor Protocol Number: CICL670ABE04 Start Date*: 2016-01-18
    Sponsor Name:Novartis Pharma NV
    Full Title: A phase II pilot study to assess the presence of molecular factors predictive for hematologic response in myelodysplastic syndrome patients receiving deferasirox therapy in hematological centers in...
    Medical condition: The study will include two groups of patients with low and intermediate 1 risk myelodysplastic syndrome. One group consists of patients who experience an hematological response while on deferasirox...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002529-12 Sponsor Protocol Number: CICL670F2203 Start Date*: 2017-10-19
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase II, multicenter, open-label, randomized two-year study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with Hereditary Hemochromatosis
    Medical condition: Hereditary Hemochromatosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000012236 10057874 Hereditary hemochromatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) SK (Completed) DE (Completed) BE (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2008-006268-12 Sponsor Protocol Number: CICL670ADE06T Start Date*: 2009-08-31
    Sponsor Name:Friedrich-Alexander-Universitaet Erlangen-Nuernberg
    Full Title: Early treatment with deferasirox (Exjade®) in low risk MDS
    Medical condition: Patients presenting with low or INT-1 risk MDS with only mild iron overload will be treated with deferasirox in this study. It will be analyzed if hematological improvement can be observed during t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014666-25 Sponsor Protocol Number: 2009-014666-25 Start Date*: 2010-01-02
    Sponsor Name:FONDAZIONE FRANCO E PIERA CUTINO
    Full Title: SEQUENTIAL DEFERASIROX-DEFERIPRONE VERSUS DEFERASIROX OR DEFERIPRONE MULTICENTRE RANDOMIZED TRIAL
    Medical condition: BETA-THALASSEMIA MAJOR
    Disease: Version SOC Term Classification Code Term Level
    12.0 10004514 Beta-thalassaemia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003482-25 Sponsor Protocol Number: CICL670F2429 Start Date*: 2018-04-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A single-arm interventional Phase IV, post-authorisation study evaluating the safety of pediatric patients with transfusional hemosiderosis treated with deferasirox crushed film coated tablets
    Medical condition: Transfusional Hemosiderosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10019613 Hemosiderosis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-018091-34 Sponsor Protocol Number: CICL670AGR02 Start Date*: 2010-07-14
    Sponsor Name:Novartis (Hellas) S.A.C.I
    Full Title: A multicenter open label phase II study to evaluate the safety and efficacy of deferasirox in combination with deferioxamine followed by transitioning to deferasirox monotherapy in β-thalassemia pa...
    Medical condition: Chronic iron overload in patients cardiac iron overload and β thalassemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043389 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-000650-64 Sponsor Protocol Number: CICL670E2419 Start Date*: 2012-11-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, multi-center, efficacy and safety study of deferasirox in iron overloaded patients with non-transfusion dependent thalassemia (THETIS)
    Medical condition: iron overload in patients with non-transfusion dependent thalassemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10022979 Iron excess HLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003230-22 Sponsor Protocol Number: CICL670AIT07 Start Date*: 2008-11-04
    Sponsor Name:NOVARTIS FARMA
    Full Title: Multicenter, open label, prospective study to evaluate the efficacy and safety of deferasirox 30 mg/kg/day for 52 weeks, in transfusion-dependent β-thalassemic patients with cardiac MRI ...
    Medical condition: cardiac iron overload
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019024 Haemosiderosis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012344-17 Sponsor Protocol Number: CICL670AIT06T Start Date*: 2009-10-13
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: A randomized, open label, single center, phase IIa controlled trial to assess tolerability, safety and effect of treatment with deferasirox plus standard antiviral therapy versus standard antivira...
    Medical condition: Chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004164-51 Sponsor Protocol Number: LPI-1/2007 Start Date*: 2008-03-26
    Sponsor Name:FONDAZIONE ITALIANA "LEONARDO GIAMBRONE"PER LA GUARIGIONE DALLA TALASSEMIA - ONLUS
    Full Title: LPI-Labile Plasma Iron in Deferasirox-Treated Thalassemic Patients
    Medical condition: thalassemic patients diagnosed with chronic iron overload due to regular blood transfusion
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043388 Thalassaemia LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000307-93 Sponsor Protocol Number: CICL670F2105 Start Date*: 2016-03-09
    Sponsor Name:Novartis Pharmaceuticals Corporation
    Full Title: A randomized, open label, single center, phase I, two way, cross-over study to evaluate the pharmacokinetic comparability of deferasirox new granule formulation with the reference dispersible formu...
    Medical condition: Healthy subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-010088-17 Sponsor Protocol Number: MID/09 Start Date*: 2009-02-16
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALI GALLIERA
    Full Title: Whole liver iron overload measured by the biosusceptometer Magnetic Iron Detector (MID) in thalassemia and MDS patients treated with deferasirox
    Medical condition: Patients with diagnosis of thalassemia major with iron overload or regularly transfused MDS patients (Low/Intermediate-1 IPSS risk and 1 year life expectancy)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010329 Congenital anaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000248-32 Sponsor Protocol Number: CICL670F2102 Start Date*: 2016-03-15
    Sponsor Name:Novartis Pharmaceuticals Corporation
    Full Title: A randomized, open-label, single center, phase I, cross-over study to evaluate the pharmacokinetic comparability of deferasirox new tablet formulation with the reference dispersible formulation in ...
    Medical condition: Healthy subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-004739-55 Sponsor Protocol Number: CICL670F2202 Start Date*: 2015-09-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open-label, multicenter, two arm, phase II study to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients with iro...
    Medical condition: transfusion-dependent anemia requiring chelation therapy due to iron overload
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10074295 Transfusion dependent anemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) BG (Completed) FR (Completed) HU (Completed) DK (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012916-41 Sponsor Protocol Number: CICL670EDE08T Start Date*: 2010-01-12
    Sponsor Name:CROLLL GmbH
    Full Title: The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (NASH) - a prospective open-label phase I/II trial
    Medical condition: To assess the clinical and biological activity of Deferasirox in patients with NASH and increased iron storage / disturbed distribution of iron on liver function and liver histology
    Disease: Version SOC Term Classification Code Term Level
    14.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 14:31:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA